Viking Therapeutics, Inc.

LSE (USD): Viking Therapeutics, Inc. (0VQA)

Last Price

27.17

Today's Change

-0.75 (2.68%)

Day's Change

26.73 - 28.23

Trading Volume

2,709

Overview

Market Cap

0

Shares Outstanding

0

Avg Volume

0

Avg Price (50 Days)

0.00

Avg Price (200 Days)

0.00

PE Ratio

0.00

EPS

0.00

Earnings Announcement

Previous Close

0.00

Open

0.00

Day's Range

0.0 - 0.0

Year Range

0.0 - 0.0

Trading Volume

0

Price Change Highlight

1 Day Change

5 Day Change

1 Month Change

3 Month Change

6 Month Change

Ytd Change

1 Year Change

3 Year Change

5 Year Change

10 Year Change

Max Change

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Pharmaceuticals, Biotechnology & Life Sciences

Description:

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment